Terminated PHASE1 INTERVENTIONAL 2-arm NCT04500574

Latanoprost Eluting Contact Lens for Treating Glaucoma and Ocular Hypertension

Sponsor: Harvard University

Interventions Latanoprost eluting contact lens Topical Latanoprost

Updated 9 times since 2020 Last updated: Oct 11, 2025 Started: Apr 3, 2024 Primary completion: Oct 10, 2025 Completion: Oct 10, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Low recruitment

Other terminated trials from Harvard University

See all terminations from Harvard University

Other Glaucoma trials with similar outcome

Browse all Glaucoma trials

A PHASE1 clinical study on Glaucoma and Ocular Hypertension, this trial is terminated or withdrawn. The trial is conducted by Harvard University and has accumulated 9 data snapshots since 2024. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

9 versions recorded

Nov 2025 — Present [monthly]

Terminated PHASE1

Status: Unknown → Terminated
May 2025 — Nov 2025 [monthly]

Unknown PHASE1

Status: Recruiting → Unknown
Sep 2024 — May 2025 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
May 2023 — Jul 2024 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting

▶ Show 4 earlier versions

Apr 2022 — May 2023 [monthly]

Not Yet Recruiting PHASE1
Mar 2021 — Apr 2022 [monthly]

Not Yet Recruiting PHASE1
Jan 2021 — Mar 2021 [monthly]

Not Yet Recruiting PHASE1
Sep 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Harvard University
Massachusetts Eye and Ear Infirmary

Data source: Massachusetts Eye and Ear Infirmary

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States